Reduced Exposure to Harmful and Potentially Harmful Smoke Constituents With the Tobacco Heating System 2.1

Frank Lüdicke, Gizelle Baker, John Magnette, Patrick Picavet, Rolf Weitkunat, Frank Lüdicke, Gizelle Baker, John Magnette, Patrick Picavet, Rolf Weitkunat

Abstract

Introduction: Heating rather than burning tobacco reduces levels of harmful and potentially harmful constituents, and consumer products using this approach aim to reduce exposure to tobacco toxicants. The Tobacco Heating System (THS) version 2.1 has been enhanced from earlier prototypes with an improved heat control and sensorial experience and thereby user acceptance. Exposure measurements are required to determine whether it may be possible to reduce the individual health risk compared to smoking combustible cigarettes (CCs).

Methods: This controlled clinical study randomly assigned 40 smokers to either a group continuing to use of their own CC brand (n = 20) or a group switching to THS 2.1 (n = 20) for 5 days. Biomarkers of exposure were measured at baseline and on day 1 through day 5. Product consumption, Human Puffing Topography, the occurrence of adverse events, and an assessment of subjective effects, such as smoking satisfaction and enjoyment of respiratory tract sensations, were also determined.

Results: The group of smokers who switched to THS 2.1 adapted their puffing behavior initially through longer puff duration and more puffs. During the duration of the study, total puff volume returned to baseline levels and the mean daily product consumption increased but with similar nicotine exposure compared to baseline CC use. Biomarkers of exposure to tobacco smoke toxicants which inform product risk assessment were significantly reduced with THS use compared to the CC group. THS 2.1 users experienced less reinforcing effects with THS 2.1 than with their own cigarette brand.

Conclusions: THS 2.1 is a promising alternative to smoking CCs. Notwithstanding possible use adaption through consumption or puffing behavior, the exposure to harmful smoke constituents was markedly reduced with the new heated tobacco platform.

Implications: Exposure markers to harmful and potentially harmful smoke constituents were lowered with the THS 2.1. Heating tobacco instead of burning can offer a potentially lower risk of delivering nicotine compared to CCs.

© The Author 2016. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco.

Figures

Figure 1.
Figure 1.
Tobacco Heating System.

References

    1. Unverdorben M, Mostert A, Munjal S, et al. Acute effects of cigarette smoking on pulmonary function. Regul Toxicol Pharmacol. 2010;57(2–3):241–246.
    1. Roethig HJ, Koval T, Muhammad-Kah R, Jin Y, Mendes P, Unverdorben M. Short term effects of reduced exposure to cigarette smoke on white blood cells, platelets and red blood cells in adult cigarette smokers. Regul Toxicol Pharmacol. 2010;57(2–3):333–337. doi:10.1016/j.yrtph.2010.04.005.
    1. Martin Leroy C, Jarus-Dziedzic K, Ancerewicz J, Lindner D, Kulesza A, Magnette J. Reduced exposure evaluation of an Electrically Heated Cigarette Smoking System. Part 7: a one-month, randomized, ambulatory, controlled clinical study in Poland. Regul Toxicol Pharmacol. 2012;64(2 suppl):S74–S84. doi:10.1016/j.yrtph.2012.08.006.
    1. Tricker AR, Kanada S, Takada K, et al. Reduced exposure evaluation of an Electrically Heated Cigarette Smoking System. Part 6: 6-day randomized clinical trial of a menthol cigarette in Japan. Regul Toxicol Pharmacol. 2012;64(2):S64–S73. doi:10.1016/j.yrtph.2012.08.007.
    1. Hughes JR, Keely JP. The effect of a novel smoking system–Accord–on ongoing smoking and toxin exposure. Nicotine Tob Res. 2004;6(6):1021–1027.
    1. Roethig HJ, Feng S, Liang Q, Liu J, Rees WA, Zedler BK. A 12-month, randomized, controlled study to evaluate exposure and cardiovascular risk factors in adult smokers switching from conventional cigarettes to a second-generation Electrically Heated Cigarette Smoking System. J Clin Pharmacol. 2008;48(5):580–591. doi:10.1177/0091270008315316.
    1. Buchhalter AR, Eissenberg T. Preliminary evaluation of a novel smoking system: effects on subjective and physiological measures and on smoking behavior. Nicotine Tob Res. 2000;2(1):39–43.
    1. Buchhalter AR, Schrinel L, Eissenberg T. Withdrawal-suppressing effects of a novel smoking system: comparison with own brand, not own brand, and de-nicotinized cigarettes. Nicotine Tob Res. 2001;3(2):111–118. doi:10.1080/14622200110042636.
    1. Fagerström KO, Hughes JR, Rasmussen T, Callas PW. Randomised trial investigating effect of a novel nicotine delivery device (Eclipse) and a nicotine oral inhaler on smoking behaviour, nicotine and carbon monoxide exposure, and motivation to quit. Tob Control. 2000;9(3):327–333.
    1. Fagerström KO, Hughes JR, Callas PW. Long-term effects of the Eclipse cigarette substitute and the nicotine inhaler in smokers not interested in quitting. Nicotine Tob Res. 2002;4(suppl 2):S141–S145. doi:10.1080/1462220021000032771.
    1. Lee EM, Malson JL, Moolchan ET, Pickworth WB. Quantitative comparisons between a nicotine delivery device (Eclipse) and conventional cigarette smoking. Nicotine Tob Res. 2004;6(1):95–102. doi:10.1080/14622200310001656911.
    1. Hatsukami DK, Biener L, Leischow SJ, Zeller MR. Tobacco and nicotine product testing. Nicotine Tob Res. 2012;14(1):7–17. doi:10.1093/ntr/ntr027.
    1. Rees VW, Kreslake JM, O’Connor RJ, et al. Methods used in internal industry clinical trials to assess tobacco risk reduction. Cancer Epidemiol Biomarkers Prev. 2009;18(12):3196–3208. doi:10.1158/1055-9965.EPI-09-0819.
    1. Kasza KA, Hyland AJ, Bansal-Travers M, et al. Switching between menthol and nonmenthol cigarettes: findings from the U.S. Cohort of the International Tobacco Control Four Country Survey. Nicotine Tob Res. 2014;16(9):1255–1265. doi:10.1093/ntr/ntu098.
    1. Kavvadias D, Scherer G, Cheung F, Errington G, Shepperd J, McEwan M. Determination of tobacco-specific N-nitrosamines in urine of smokers and non-smokers. Biomarkers. 2009;14(8):547–553. doi:10.3109/13547500903242883.
    1. Uppsala Monitoring Centre. WHO Drug Dictionary Enhanced (WHO DDE). 2012. Accessed November 3, 2014.
    1. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991;86(9):1119–1127.
    1. Cappelleri JC, Bushmakin AG, Baker CL, Merikle E, Olufade AO, Gilbert DG. Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire. Addict Behav. 2007;32(5):912–923. doi:10.1016/j.addbeh.2006.06.028.
    1. Philip Morris Products S.A. A Controlled, Randomised, Open-Label, 3-Arm Parallel Single-Centre Confinement Study to Investigate Exposure to Selected Smoke Constituents in Smokers Switching From Conventional Cigarettes to SMAR Cigarettes for 5 Days [YVD-CS01-EU]. [Internet]. Bethesda, MD: National Library of Medicine (US); 2008. –2009. Accessed December 2, 2013.
    1. FDA (Food and Drug Administration). Guidance for Industry - Reporting Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke Under Section 904(a)(3) of the Federal Food, Drug, and Cosmetic Act - Draft Guidance. 2012.
    1. Forster M, Liu C, Duke MG, McAdam KG, Proctor CJ. An experimental method to study emissions from heated tobacco between 100–200degrees C. Chem Cent J. 2015;9:20. doi:10.1186/s13065-015-0096-1.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj